SecBot SecBot
PRESS-RELEASE ·Filed Jun 11, 2026

CRBU

Caribou Biosciences, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The deep and durable efficacy data, including activity after prior approved CAR-T, are encouraging for CB-011's differentiation. Watch for the dose expansion data in H2 2026, which will further inform the registrational path. The company's ability to fund a pivotal Phase 3 is a key risk given its ~$178M market cap.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$1.66
T+0 close · Jun 11, 2026 · via day close
Latest settled
+16.87%
T+20 · $1.94
Vs SPY
+14.98%
α at T+20
Next horizon
T+60
due 2mo ago
  1. T+0 · Jun 11 $1.66entry
  2. T+1 · 5mo ago −3.92%α −4.46% · $1.60
  3. T+5 · 5mo ago −1.20%α −1.64% · $1.64
  4. T+20 · 4mo ago +16.87%α +14.98% · $1.94
  5. T+60 · due 2mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Caribou Biosciences reported longer follow-up data from the CaMMouflage Phase 1 trial of CB-011, an off-the-shelf BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma. In the BCMA-naïve recommended dose expansion cohort (n=12), results showed a 92% ORR, 83% CR/≥CR rate, 91% MRD negativity, and 50% of patients sustaining ≥CR at 15 months, with a manageable safety profile. These data will be presented at EHA on June 14, 2026, and initial dose expansion data in both BCMA-naïve and BCMA-exposed patients are expected in H2 2026.

Key Facts

  • Single dose of CB-011 at the 450M cell RDE produced 92% ORR, 83% CR/≥CR rate, 91% MRD negativity in BCMA-naïve patients (n=12).
  • 50% of patients in the BCMA-naïve RDE cohort maintained ≥CR at 15 months; median follow-up 17.7 months.
  • A case study of a patient who had failed approved autologous CAR-T (cilta-cel) achieved CR by day 28 with CB-011.
  • Safety profile was manageable with no GvHD, parkinsonism, or cranial nerve palsies; one (8%) ≥Gr 3 CRS, no ≥Gr 3 ICANS at RDE.
  • EHA oral presentation scheduled for June 14, 2026; initial dose expansion data expected in H2 2026.
  • CB-011 has FDA RMAT, Fast Track, and Orphan Drug designations for r/r multiple myeloma.

Financial Impact

No financial figures were disclosed. These are clinical data only.

Risk Factors

  • CaMMouflage Phase 1 is still ongoing with a small dataset (n=48 total); larger expansion cohorts may show different results.
  • CB-011 faces competition from approved BCMA CAR-Ts and other allogeneic approaches; commercial adoption is uncertain.
  • Caribou's limited financial resources and history of operating losses could constrain further development and pivotal trial funding.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3310377

Track record

13 reports on CRBU

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 5, 202611d ago 8-K Bearish 7/10 Entry $0.4487 Now $0.3530 +21.33% settles Dec 7
  2. Oct 6, 20265w ago 8-K Bearish 7/10 Entry $0.6174 to $0.4444 Now $0.3530 +42.82% ▲ +28.02% +26.68% vs SPY
  3. Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $1.34 to $0.5190 Now $0.3530 −73.66% ▼ −61.27% −60.71% vs SPY
  4. Jun 11, 202622w ago 8-K Bullish 6/10 Entry $1.66 to $1.94 Now $0.3530 −78.73% ▲ +16.87% +14.98% vs SPY
  5. Jun 11, 202622w ago Press Release Bullish 7/10 Viewing Entry $1.66 to $1.94 Now $0.3530 −78.73% ▲ +16.87% +14.98% vs SPY
  6. Jun 5, 202623w ago DEFA14A Neutral 2/10 Entry $1.84 to $1.83 Now $0.3530 −80.82% ▼ −0.54% −2.17% vs SPY
  7. Apr 24, 202629w ago DEFA14A Neutral 3/10 Entry $2.13 to $2.16 Now $0.3530 −83.43% ▲ +1.41% −3.55% vs SPY
  8. Mar 5, 202636w ago 8-K Mixed 5/10 Entry $1.82 to $1.95 Now $0.3530 −80.60% ▲ +7.14% +9.19% vs SPY
  9. Mar 5, 202636w ago Press Release Mixed 6/10 Entry $1.82 to $1.95 Now $0.3530 −80.60% ▲ +7.14% +9.19% vs SPY
  10. Feb 28, 202637w ago Institutional Cluster Neutral 5/10 Entry $1.84 to $1.72 Now $0.3530 −80.82% ▼ −6.52% +1.42% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 6h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 11, 2026